Phase 3
N=47
Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure
Heart Failure
Bottom Line
View on ClinicalTrials.gov: NCT05093621 ↗Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcome: Primary: Number of Participants All-cause Mortality, Measured at 1 Year. — 0; 0; 0; 1 Participants — p=1.000
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Furosemide (Drug); Torsemide (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Yale University
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants All-cause Mortality, Measured at 1 Year. |
0; 0; 0; 1 | 1.000 |
| SECONDARY All-cause Hospitalization |
6; 7 | 0.729 |
| SECONDARY Total Hospitalizations |
0; 0 | 0.650 |
| SECONDARY Change in Weight |
-1.84; -3.04 | 0.873 |
Summary
The study is designed to be a prospective, randomized study is to compare the effectiveness of two standard of care loop diuretics (furosemide versus torsemide) on clinical outcomes among patients currently on a stable dose of loop diuretics.
Eligibility Criteria
Inclusion Criteria
- Patients with a diagnosis of heart failure and who have been on a stable dose of a diuretic for at least 30 days.
- Plan for a daily outpatient oral loop diuretic regimen with anticipated need for long term loop diuretic use
- ≥ 18 years of age
- Signed informed consent
Exclusion Criteria
- End-stage renal disease requiring dialysis therapy
- Inability or unwillingness to comply with the study requirements
- History of heart transplant or actively listed for heart transplant
- Implanted left ventricular assist device or implant anticipated <3 months
- Pregnant or nursing women or women who are trying to conceive
- Malignancy or other non-cardiac condition limiting life expectancy to <12 months
- Known hypersensitivity to furosemide, torsemide, or related agents
Data sourced from ClinicalTrials.gov (NCT05093621). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.